In contrast to the above mentioned combination strategies tested in the overall previously treated R/M cervical cancer population regardless of PD-L1 status, the anti-PD-1 sintilimab was tested in combination with the multikinase inhibitor anlotinib in a phase II trial, demonstrating its safety and efficacy as second-line or later therapy just for R/M CC patients expressing PD-L1 (Table 1). This evidence concerns the gene CD274 and cervical cancer.